[1] Miller KD,Siegel RL,Lin CC,et al. Cancer treatment and survivorship statistics, CA cancer J CLIN,2016,66(4):271-89.
[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017.CA Cancer J Clin. 2017; 67:7–30.
[3] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of
thyroid, liver, and pancreas cancers in the United States. Caner Res. 2014;
74(14):2913–2.
[4] Pu N, lv Y, Zhao G, Lee W, Nuerxiati A, Wang D, Xu X, Kuang T, Wu W, Lou
W. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Future Oncol. 2018;14(2):165–75.
[5] Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–988.
[6] Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific
metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23 (10):1872–1880.
[7] Tao L, Yuan C, Ma Z, Jiang B, Xiu D,et al. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res.2017;9:471-479.
[8] Fang C, Wang W, Feng X, Sun J, Zhang Y, et al. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2017;117:1544–1550.
[9] Zhou H, Zhang Y, Qiu Z, Chen G, Hong S, et al. Nomogram to predict cause-specific mortality in patients with surgically resected Stage I non–small-cell lung cancer: A competing risk analysis. Clin Lung Cancer.2017; 2:195–203.
[10] Iasonos, A., Schrag, D., Raj, G. V. & Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. Journal of Clinical Oncology.2008; 26:1364–1370.
[11] Zhang ZY, Luo QF, Yin XW, Dai ZL, Basnet S, and Ge HY. Nomograms to predict survival after colorectal cancer resection without preoperative therapy. BMC Cancer 2016;16:658.
[12] Junjie Hang, Lixia Wu, Lina Zhu,et al. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer Med. 2018;7(7): 2974–2984.
[13] Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007; 110: 2484-2492.
[14] Dünschede F, Will L, von Langsdorf C, Möhler M, Galle PR, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res .2010; 44: 209-213.
[15] Wang Lai, Yang Lina, Chen Lianyu et al. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis.[J] .Med. Sci. Monit., 2019, 25: 8230-8241.
[16] Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, Hines OJ, Donahue TR, Reber HA, Tomlinson JS. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
Ann Surg Oncol. 2013;20(13):4322–9.
[17] He C, Zhang Y, Cai Z, Lin X, Li S. Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: a competing risk nomogram analysis. J Cancer. 2018;9(17):3156–67.
[18] Rochefort MM1, Ankeny JS, Kadera BE, et al.Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System. Ann Surg Oncol. 2013;20(13):4322-9.
[19] Hlavsa J, Cecka F, Zaruba P, et al. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Neoplasma. 2018;65(4):637-643.
[20] Ikeda M, Ioka T, Ito Y,et al.A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys.2013;85(1):163-169.
[21] Blackstock AW,Tepper JE,Niedwiecki D,et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.Int J Gastrointest Cancer.2003;34(2-3):107-116.
[22] Huguet F,Girard N,Guerche CS,et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.J Clin Oncol.2009;27(13):2269-2277.
[23] Hudson E,Hurt C,Mort D,et al.Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.Clin Oncol (R Coll Radiol). 2010;22(1):27-35.
[24] Reni M,Cereda S,Balzano G,et al.Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.Cancer Chemother Pharmacol. 2009;64(6):1253-1259.
[25] Sultana Asma, Smith Catrin Tudur, Cunningham David et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer[J] .J. Clin. Oncol., 2007, 25: 2607-15.
[26] Blazer Marlo, Wu Christina, Goldberg Richard M et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.[J] .Ann. Surg. Oncol., 2015, 22: 1153-9.
[27] Kanda Mitsuro, Fujii Tsutomu, Nagai Shunji et al. Pattern of lymph node metastasis spread in pancreatic cancer.[J] .Pancreas, 2011, 40: 951-5.
[28] Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156:591-600.
[29] Eskander MF, de Geus SW, Kasumova GG, et al. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Surgery 2017;161:968-976.
[30] International Bladder Cancer Nomogram Consortium, Bochner Bernard H, Kattan Michael W et al. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.[J] .J. Clin. Oncol., 2006, 24: 3967-72.
[31] Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer(PROLAP). Br J Cancer.2016;115:281–289.
[32] Yi-Nan Shen, Xue-Li Bai, Gang Jin, et al. A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. HPB (Oxford). 2018 Nov;20(11):1034-1043.